Market Place
Sourcing Support
All News #Library
Biotech
Evommune Hosts KOL Webinar Showcasing MRGPRX2 Inhibition
06 Apr 2026 //
PHARMIWEB
Evommune`s Dupixent-Like Eczema Data Drive 75% Stock Rally
10 Feb 2026 //
FIERCE BIOTECH
Evommune Reveals Q3 2025 Financials And Business Update
11 Dec 2025 //
BUSINESSWIRE
Evommune Closes IPO With Full Underwriters Option Exercise
08 Nov 2025 //
PR NEWSWIRE
Evommune Announces Pricing Of Its Initial Public Offering
05 Nov 2025 //
PR NEWSWIRE BIO
Evommune To Raise $160M In IPO For Immuno Pipeline
31 Oct 2025 //
BIOSPACE
Evommune Announces Commencement Of Initial Public Offering
30 Oct 2025 //
PR NEWSWIRE
Inflammation Biotech Evommune Eyes IPO To Fund Dermatitis Trials
10 Oct 2025 //
FIERCE BIOTECH
Evommune Shares Full Ph 2 Data for EVO756 in Chronic Urticaria
19 Sep 2025 //
PR NEWSWIRE
Evommune to Present EVO756 Phase 2 Data for Chronic Inducible
02 Sep 2025 //
PR NEWSWIRE
Evommune to Participate in Three Upcoming Investor Conferences
28 Aug 2025 //
PR NEWSWIRE
Evommune Starts Phase 2b Trial for Oral MRGPRX2 Antagonist
27 Aug 2025 //
PR NEWSWIRE
Evommune Releases Phase 2 Trial Data on EVO756 in Urticaria
28 May 2025 //
PR NEWSWIRE
Evommune Begins Phase 2b Trial of MRGPRX2 Antagonist EVO756
15 Apr 2025 //
PR NEWSWIRE
Evommune Starts Phase 2 Trial of EVO301 in Atopic Dermatitis
17 Mar 2025 //
PR NEWSWIRE
Evommune Presents Positive EVO756 Data At GA²LEN Urticaria Forum
04 Dec 2024 //
PR NEWSWIRE
Evommune Begins Phase 2 Trial of EVO756 in Chronic Inducible Urticaria
03 Sep 2024 //
PR NEWSWIRE
Evommune Secures Rights to Commercialize IL-18 Fusion Protein From AprilBio
24 Jun 2024 //
PR NEWSWIRE
Evommune and Accutar Biotechnology Announce AI Drug Discovery Collaboration
28 Nov 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.